Johnson & Johnson (JNJ) Tuesday said it has submitted supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to include new evidence in the TREMFYA label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).
The submission is supported by the Phase 3b APEX study in patients with active PsA, which met its primary endpoint of reducing joint symptoms and major secondary endpoint of inhibited progression of structural damage.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.